The global noninvasive hemoglobin monitoring device market size was valued at USD 771.33 billion in 2025 and is projected to grow from USD 826.71 billion in 2026 to USD 1439.67 billion by 2034, registering a CAGR of 7.18% during the forecast period (2026–2034). North America dominated the noninvasive hemoglobin monitoring device market with a share of 38.5% in 2025.
A noninvasive hemoglobin monitoring device is a medical device that estimates hemoglobin levels in the blood without requiring a blood sample. Noninvasive hemoglobin monitoring devices are generally tracked under HSN Code 9018 (instruments and appliances used in medical, surgical, dental, or veterinary sciences) and SIC Code 3845 (electromedical and electrotherapeutic apparatus).
The noninvasive hemoglobin monitoring device market demand is driven by the growing need for rapid and painless hemoglobin assessment and the increasing focus on convenient patient monitoring. The adoption of noninvasive hemoglobin monitoring devices and continuous monitoring technologies contributes to noninvasive hemoglobin monitoring device market growth.
By Product Type
By Technology
By End User
Download a Free Sample To learn more about this report,
Shift Toward AI and Advanced Signal Processing
The noninvasive hemoglobin monitoring device market analysis shows a shift toward the use of AI and advanced signal processing is improving the way noninvasive hemoglobin devices analyze optical signals from the body. These technologies help reduce the effect of factors such as movement, skin characteristics, and other signal disturbances, supporting more reliable hemoglobin readings. This development is improving the accuracy and usability of noninvasive monitoring devices in hospitals, clinics, and point-of-care settings.
Preference for Wearable Hemoglobin Monitoring Devices
The interest in continuous and convenient health monitoring is encouraging the development of wearable devices that can track hemoglobin levels without repeated blood collection. These devices can use optical sensors placed on the skin to collect readings during daily activities, making monitoring more comfortable and convenient for patients. The trend is supporting the use of wearable hemoglobin monitoring in remote care, chronic disease management, and home-based healthcare.
Supply chain disruptions are expected to have a high impact on the noninvasive hemoglobin monitoring device market share due to dependence on optical sensors, semiconductor components, photodetectors, microprocessors, medical-grade electronics, and specialized manufacturing and distribution networks. The market is expected to follow a U-shaped recovery, as shortages of electronic components, extended procurement lead times, manufacturing delays, and regulatory-related supply constraints can prolong disruptions before device production and hospital deliveries return to stable levels. The market is expected to grow at a CAGR of 7.18%, but supply chain constraints could approximately lower this by 1.3 percentage points, resulting in short-term growth of around 5.88%. As supply conditions normalize through improved semiconductor and sensor availability, stabilized component prices, expanded manufacturing capacity, and smoother medical-device logistics, noninvasive noninvasive hemoglobin monitoring device market growth is expected to gradually return to 7.18%.
Adoption of Pulse CO-Oximetry in Critical Care and Demand for Point-of-Care Testing (POCT) Drives Market
The noninvasive hemoglobin monitoring device market analysis shows a shift toward the increasing use of pulse CO-oximetry in critical care. Critical care settings require frequent assessment of hemoglobin and other blood parameters to support timely patient management. Pulse CO-oximetry provides continuous measurements without repeated blood draws, which can reduce patient discomfort and testing time.
The demand for point-of-care testing (POCT) in clinical settings is increasing the need for portable devices that provide rapid hemoglobin measurements. Hospitals and emergency care units require quick test results to support faster clinical decisions. Noninvasive devices can provide hemoglobin readings near the patient without depending on centralized laboratory testing. This convenience supports their use across emergency departments, critical care units, and other clinical settings.
Limited Accuracy in Certain Clinical Conditions and Competition from Conventional Hemoglobin Testing Restraints Market Expansion
Limited accuracy in certain clinical conditions can affect the reliability of noninvasive hemoglobin measurements. Factors such as poor peripheral circulation, skin pigmentation, low perfusion, motion, and changes in blood volume can influence optical measurements. These variations may create differences between noninvasive readings and laboratory-based hemoglobin results. Such accuracy concerns can make healthcare providers more cautious about using these devices for critical clinical decisions and limit market adoption.
Competition from conventional hemoglobin testing can limit the adoption of noninvasive monitoring devices in healthcare settings. Laboratory-based methods such as complete blood count (CBC) testing provide established and widely accepted hemoglobin measurements. Hospitals and diagnostic laboratories already have the equipment, procedures, and trained staff required for these tests.
Expansion of Hemoglobin Screening in Blood Donation and Performance Monitoring Creates New Revenue Avenues for Market Players
Noninvasive hemoglobin device manufacturers and medical equipment suppliers can target blood banks, blood donation centers, and transfusion organizations that require efficient donor screening. These facilities can use the devices to assess donor eligibility while reducing the need for routine blood sampling. The growing blood donation activities therefore create revenue opportunities through device sales, bulk procurement contracts, screening programs, installation, and maintenance services.
Sports technology companies, medical device providers, athletic training centers, and performance-monitoring organizations can target athletes and sports teams seeking convenient physiological assessments. These applications can support athlete monitoring during training, fitness assessment, and performance management without frequent blood collection. The rising interest in sports health monitoring therefore creates revenue opportunities through specialized device sales, institutional contracts, monitoring services, and partnerships with sports organizations.
Reimbursement & Procurement Challenges and Stringent Regulatory Approval Requirements Limit Healthcare Adoption Hinders Market Growth
Unclear reimbursement pathways and differences in healthcare procurement policies can make it difficult for providers to justify investments in noninvasive hemoglobin monitoring devices. Hospitals may require evidence of clinical value, cost savings, and workflow benefits before including these devices in procurement programs. Lengthy purchasing procedures can delay sales and deployment.
Noninvasive hemoglobin monitoring devices must meet strict regulatory requirements related to safety, clinical performance, device quality, and manufacturing processes before entering many healthcare markets. Clinical evaluations, documentation, validation studies, and regulatory reviews can require significant time and resources. Smaller companies may face greater difficulty managing these approval processes, which can slow innovation and market expansion.
The continuous hemoglobin monitoring devices segment accounted for a share of 42% in 2025 due to their ability to provide real-time hemoglobin trends without repeated blood sampling. Their use in patient blood management, surgery, and critical care supports segment demand.
The multi-parameter systems segment is expected to grow at a CAGR of 7% during the forecast period, driven by the demand for devices that monitor hemoglobin along with oxygen saturation and other blood-related parameters.
Request Customizationto receive a tailored report.
The pulse CO-oximetry segment accounted for a share of 46% in 2025 due to its ability to measure hemoglobin noninvasively using multiple wavelengths of light. Its application in continuous and spot-check hemoglobin monitoring across clinical settings supports segment demand.
The computer vision-based estimation segment is expected to grow at a CAGR of 10.1% during the forecast period, fueled by increasing development of AI-based systems that estimate hemoglobin levels from images.
The hospitals & clinics segment accounted for a share of 48% in 2025 due to the high need for rapid and continuous hemoglobin monitoring during surgery, critical care, anemia assessment, and patient blood management.
The home healthcare segment is expected to grow at a CAGR of 9.4% during the forecast period, supported by increasing demand for convenient and noninvasive patient monitoring outside traditional healthcare facilities.
Speak to an Analystto discuss market opportunities.
Market Dominance Led by Advanced Patient Monitoring Infrastructure and Adoption of Pulse CO-Oximetry
The North America noninvasive hemoglobin monitoring device market accounted for the largest regional share of 38.5% in 2025, supported by advanced healthcare infrastructure, widespread adoption of point-of-care monitoring, and increasing use of continuous patient-monitoring technologies.
The United States noninvasive hemoglobin monitoring device market size was valued at USD 85 million in 2025. In the U.S., the Veterans Health Administration initiated a feasibility project to evaluate noninvasive SpHb monitoring for identifying anemia among hospitalized veterans with recurrent bleeding, iron deficiency, or bleeding disorders, demonstrating the use of noninvasive hemoglobin monitoring in clinical care.
The Canada noninvasive hemoglobin monitoring device market size was valued at USD 20 million in 2025, supported by increasing adoption of point-of-care diagnostic technologies and advanced patient monitoring. The availability of Masimo’s rainbow pulse CO-oximetry technology, which enables noninvasive monitoring of total hemoglobin alongside parameters such as methemoglobin and carboxyhemoglobin, provides Canadian healthcare providers with a multi-parameter approach to patient monitoring.
Unlock Regional Insightsto access country-level data, & regional trends.
Fastest Growth Led by Expanding Healthcare Infrastructure and Adoption of Surgical Procedures
The Asia Pacific noninvasive hemoglobin monitoring device market is expected to grow at a CAGR of 9.6% during the forecast period, making it the fastest-growing regional market, owing to rapid hospital infrastructure modernization, increasing healthcare access, and rising surgical procedures.
The China noninvasive hemoglobin monitoring device market size size was valued at USD 0.7 billion in 2025, supported by expanding hospital infrastructure and increasing adoption of advanced diagnostic technologies. China’s hospital modernization is increasing demand for sensor-based patient monitoring, with domestic medical-device manufacturers such as Mindray expanding advanced monitoring technologies across tier-2 and tier-3 hospitals, supporting broader access to noninvasive diagnostic solutions.
The India noninvasive hemoglobin monitoring device market size was valued at 0.10 billion in 2025, fueled by expanding healthcare access and increasing demand for accessible anemia screening technologies. India’s Anaemia Mukt Bharat initiative has deployed digital hemoglobinometers at the village level and supports hemoglobin testing through government health facilities, creating demand for portable and noninvasive hemoglobin measurement technologies across primary and secondary healthcare settings.
The Japan noninvasive hemoglobin monitoring device market size was valued at 0.35 billion in 2025, driven by an aging population, advanced healthcare infrastructure, and strong adoption of medical monitoring technologies. Japanese medical device manufacturer Nihon Kohden has integrated hemoglobin measurement capabilities into its patient-monitoring portfolio, strengthening the availability of sensor-based monitoring technologies across hospitals and supporting the development of advanced noninvasive patient monitoring in Japan.
Market Growth Supported By Focus on Patient Monitoring and Advanced Medical Technology Adoption
The Europe noninvasive hemoglobin monitoring device market is expected to grow at a CAGR of 6.5%, during the forecast period. Growth is driven by the adoption of point-of-care diagnostics, demand for minimally invasive monitoring, and greater focus on patient blood management.
The UK noninvasive hemoglobin monitoring device market size was valued at 0.25 billion in 2025, driven by demand for rapid patient monitoring and point-of-care diagnostics across surgical and hospital settings. UK clinical research has specifically evaluated point-of-care hemoglobin devices for guiding transfusion decisions during surgery, reflecting increasing interest in rapid hemoglobin assessment as part of perioperative monitoring.
The Germany noninvasive hemoglobin monitoring device market size was valued at 0.35 billion in 2025, supported by advanced medical technology adoption and growing use of sensor-based patient monitoring. A study at University Hospital Würzburg evaluated Masimo’s Rad-67 Pulse CO-Oximeter sensor alongside conventional blood-gas analysis to assess noninvasive SpHb measurements in perioperative patients, demonstrating the application of medical sensors technology for continuous hemoglobin monitoring in German clinical settings.
Market Expansion Driven by Growing Critical Care Monitoring and Anesthesia Monitoring Requirements
The Latin America noninvasive hemoglobin monitoring device market is expected to grow at a CAGR of 7.1% during the forecast period, supported by expanding critical care infrastructure, increasing surgical procedures, and rising demand for continuous patient monitoring technologies. Brazilian clinical research has evaluated noninvasive hemoglobin monitoring in surgical intensive care settings, supporting its potential use for critical-care monitoring. In Mexico, Philips Healthcare offers IntelliVue patient monitors integrated with noninvasive total hemoglobin monitoring technology, supporting continuous hemoglobin assessment in critical-care and perioperative settings.
Market Expansion Led by Rising Hospital Modernization
The Middle East & Africa noninvasive hemoglobin monitoring device market is expected to grow at CAGR of 6.9% during the forecast period. Saudi Arabia’s hospital expansion is creating demand for patient monitoring systems, with new hospital capacity requiring equipment for vital signs and continuous bedside monitoring. In South Africa, CliniTouch is being used for remote monitoring of patients with chronic conditions, allowing healthcare teams to track patients remotely and reduce unnecessary hospital admissions, demonstrating the growing use of connected monitoring technologies beyond traditional hospital settings.
The noninvasive hemoglobin monitoring device market competitive landscape is moderately fragmented, with established medical device manufacturers, diagnostic technology companies, patient monitoring providers, and specialized noninvasive monitoring technology developers. Key players such as Masimo (US), OrSense Ltd. (Israel), Robert Bosch GmbH (Germany), Sysmex Corporation (Japan), and Nihon Kohden Corporation (Japan), with these five companies estimated to account for approximately 35–40% of the global noninvasive hemoglobin monitoring device market share.
Established players compete mainly through measurement accuracy, device reliability, technological innovation, clinical validation, product integration, and regulatory approvals. Emerging and regional players focus in the noninvasive hemoglobin monitoring device market ecosystem on compact devices, cost-effective solutions, faster measurements, and specialized monitoring technologies.
August 2026: Masimo received FDA 510(k) clearance for its Root with LiDCO hemodynamic monitoring solution, combining continuous noninvasive SpHb hemoglobin measurement with pulse oximetry and cardiac-output monitoring to provide continuous assessment of oxygen delivery.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Hospital Gowns Market Size, Share, Growth, Analysis, Report, 2034
Home Infusion Therapy Market Size, Share, Growth, Analysis, 2034
Point-Of-Care Molecular Diagnostics Market Size, Share, 2034
Sterilization Monitoring Market Size, Share, Growth, Analysis, Report, 2034
Europe Dental Intraoral Scanners Market Size, 2034
Rehabilitation Equipment Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com